UPDATE: Jefferies Raises PT on Insulet to $24 (PODD)

Jefferies is out with its report today on Insulet PODD, raising its PT from $20 to $24. In a note to clients, Jefferies writes, "As profitability is emerging, EV/Sales is the best valuation method. We use the 6.4x current multiple rolled forward to 2012 EV/Sales to arrive at a $24/share target and we rate PODD Buy." Shares of PODD closed Monday at $20.58.